Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMLOS5R)

Drug Name
BAY 80-6946 Drug Info
Synonyms
Copanlisib; BAY-80-6946; Aliqopa; UNII-WI6V529FZ9; BAY80-6946; WI6V529FZ9; AK172384; BAY 80-6946 (Copanlisib); Copanlisib [USAN:INN]; Copanlisib (USAN/INN); GTPL7875; SCHEMBL1655478; SCHEMBL13084037; Copanlisib (BAY 80-6946); DTXS
Indication
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [1]
Non-hodgkin lymphoma 2B33.5 Approved [2]
Cross-matching ID
PubChem CID
135565596
CAS Number
CAS 1032568-63-0
TTD Drug ID
DMLOS5R
INTEDE Drug ID
DR0378
ACDINA Drug ID
D00965

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase alpha (PIK3CA) TTEUNMR PK3CA_HUMAN Inhibitor [1]
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [1]
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Modulator [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [4]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Approved [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
PI3-kinase delta (PIK3CD) DTT PIK3CD 5.711 5.814 6.011 6.508
PI3-kinase alpha (PIK3CA) DTT PIK3CA 4.296 5.09 4.576 4.744
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 5.952 6.384 4.897 6.293
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Follicular lymphoma
ICD Disease Classification 2A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase gamma (PIK3CG) DTT PIK3CG 1.98E-01 -0.05 -0.55
Cytochrome P450 1A1 (CYP1A1) DME CYP1A1 6.63E-01 3.55E-01 4.13E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.76E-01 -4.64E-01 -9.16E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30.
4 FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration.